Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of gantenerumab in people at risk for or in the earliest stages of Alzheimer's disease
2021-001184-25Phase 3Active
- Sponsor
- Roche
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Gantenerumab with Placebo control (2 arms). Primary endpoint: Change from baseline to Year 4 in PACC-5 score. Started Dec 2021; status: active.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2021-001184-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001184-25.